Abstract
Atypical haemolytic uraemic syndrome (aHUS) is a rare disease affecting approximately 170 people in the UK. The outcome is often poor, with 53% of familial cases and 37% of sporadic cases resulting in end stage renal failure or death. A systematic review was undertaken to assess the efficacy and safety of eculizumab for aHUS. We report key outcomes and highlight issues of applying standard systematic review methods where the evidence base is not well developed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
